Proteomics International Laboratories has been granted a US patent for its endometriosis diagnostic test, PromarkerEndo. Multiple outlets report that the patent strengthens the company’s intellectual property position as it moves toward commercial rollout of the test. The coverage states that the company’s next steps include bringing the diagnostic product to the US market, described as the world’s biggest healthcare market. One source also notes that the patent is associated with a market reaction: shares in Proteomics International Laboratories rise following the announcement. Across the articles, the emphasis is on the patent award and its role in supporting planned expansion. The reports do not add differing technical details about how the test works or provide specific timing for launch, focusing instead on the patent approval and the company’s intent to scale distribution in the United States.